Ampiroxicam | CAS#99464-64-9 | COX-1 & COX-2 Inhibitor

MedKoo Cat#: 524230 | Name: Ampiroxicam

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ampiroxicam is a COX-1 and COX-2 inhibitor with anti-inflammatory activity.

Chemical Structure

Ampiroxicam

CAS#99464-64-9

Theoretical Analysis

MedKoo Cat#: 524230

Name: Ampiroxicam

CAS#: 99464-64-9

Chemical Formula: C20H21N3O7S

Exact Mass: 447.1100

Molecular Weight: 447.46

Elemental Analysis: C, 53.68; H, 4.73; N, 9.39; O, 25.03; S, 7.17

Price and Availability

Size	Price	Availability	Quantity
1g	USD 350.00	2 Weeks
5g	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Ampiroxicam; Flucam; Ampiroxicamum; CP 65703; CP-65703;

IUPAC/Chemical Name

ethyl (1-((2-methyl-1,1-dioxido-3-(pyridin-2-ylcarbamoyl)-2H-benzo[e][1,2]thiazin-4-yl)oxy)ethyl) carbonate

InChi Key

LSNWBKACGXCGAJ-UHFFFAOYSA-N

InChi Code

InChI=1S/C20H21N3O7S/c1-4-28-20(25)30-13(2)29-18-14-9-5-6-10-15(14)31(26,27)23(3)17(18)19(24)22-16-11-7-8-12-21-16/h5-13H,4H2,1-3H3,(H,21,22,24)

SMILES Code

CCOC(OC(OC1=C(C(NC2=CC=CC=N2)=O)N(C)S(=O)(C3=CC=CC=C31)=O)C)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 447.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Ishihara M, Ohmiya N, Nakamura M, Funasaka K, Miyahara R, Ohno E, Kawashima H, Itoh A, Hirooka Y, Watanabe O, Ando T, Goto H. Risk factors of symptomatic NSAID-induced small intestinal injury and diaphragm disease. Aliment Pharmacol Ther. 2014 Sep;40(5):538-47. doi: 10.1111/apt.12858. Epub 2014 Jul 4. PubMed PMID: 25041257. 2: Shirako J, Kawasaki M, Komine K, Kunisue Y, Terada M, Sasaki C, Irie W, Murakami C, Tonooka K, Tomobe K, Shinozuka T. Simultaneous determination for oxicam non-steroidal anti-inflammatory drugs in human serum by liquid chromatography-tandem mass spectrometry. Forensic Sci Int. 2013 Apr 10;227(1-3):100-2. doi: 10.1016/j.forsciint.2012.11.016. Epub 2012 Dec 27. PubMed PMID: 23273940. 3: Tasaki Y, Yamamoto J, Omura T, Noda T, Kamiyama N, Yoshida K, Satomi M, Sakaguchi T, Asari M, Ohkubo T, Shimizu K, Matsubara K. Oxicam structure in non-steroidal anti-inflammatory drugs is essential to exhibit Akt-mediated neuroprotection against 1-methyl-4-phenyl pyridinium-induced cytotoxicity. Eur J Pharmacol. 2012 Feb 15;676(1-3):57-63. doi: 10.1016/j.ejphar.2011.11.046. Epub 2011 Dec 7. PubMed PMID: 22182582. 4: Choi KH, Shim JH, Huong LD, Cho NP, Cho SD. Inhibition of myeloid cell leukemia-1 by tolfenamic acid induces apoptosis in mucoepidermoid carcinoma. Oral Dis. 2011 Jul;17(5):469-75. doi: 10.1111/j.1601-0825.2010.01774.x. Epub 2010 Dec 23. PubMed PMID: 21496182. 5: Shim JH, Shin JA, Jung JY, Choi KH, Choi ES, Cho NP, Kong G, Ryu MH, Chae JI, Cho SD. Chemopreventive effect of tolfenamic acid on KB human cervical cancer cells and tumor xenograft by downregulating specificity protein 1. Eur J Cancer Prev. 2011 Mar;20(2):102-11. doi: 10.1097/CEJ.0b013e328341e38f. PubMed PMID: 21131823. 6: Aoki T, Yamaguchi H, Naito H, Shiiki K, Izawa K, Ota Y, Sakamoto H, Kaneko A. Premedication with cyclooxygenase-2 inhibitor meloxicam reduced postoperative pain in patients after oral surgery. Int J Oral Maxillofac Surg. 2006 Jul;35(7):613-7. Epub 2006 Mar 15. PubMed PMID: 16540287. 7: Shimatani T, Inoue M, Yokoya H, Daimaru Y. Evaluation of gastric acid secretion in two patients (each aged over 90 years) with Helicobacter pylori-negative nonsteroidal anti-inflammatory drug-caused duodenal ulcers. J Gastroenterol. 2003;38(2):164-9. PubMed PMID: 12640531. 8: Honnma T, Imaizumi T, Chiba M, Niwa J. [Preemptive analgesia for postoperative pain after frontotemporal craniotomy]. No Shinkei Geka. 2002 Feb;30(2):171-4. Japanese. PubMed PMID: 11857941. 9: Sai S, Fujii K, Hiranuma K, Sato T, Nemoto T. Preoperative ampiroxicam reduces postoperative pain after hand surgery. J Hand Surg Br. 2001 Aug;26(4):377-9. PubMed PMID: 11469844. 10: Yuasa H, Kurita K; Treatment Group on Temporomandibular Disorders. Randomized clinical trial of primary treatment for temporomandibular joint disk displacement without reduction and without osseous changes: a combination of NSAIDs and mouth-opening exercise versus no treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Jun;91(6):671-5. PubMed PMID: 11402280. 11: Sasaki T, Tokuyama S, Shimizu H, Kawada H, Soh I, Sueki H, Iijima M, Yamamoto T, Kuroiwa Y. Differential property of antigenic characterization between piroxicam and ampiroxicam in contact hypersensitivity. Res Commun Mol Pathol Pharmacol. 1999;105(1-2):147-54. PubMed PMID: 10850378. 12: Nishimura M, Uzu T, Inenaga T, Kimura G. Membranous nephropathy induced by treatment with ampiroxicam, a nonsteroidal antiinflammatory drug. Nephron. 1999;83(3):272-3. PubMed PMID: 10529636. 13: Sasaki T, Shimizu H, Tokuyama S, Hariya T, Soh I, Sueki H, Iijima M, Yamamoto T, Kuroiwa Y. Antigenic characterization in ampiroxicam-induced photosensitivity using an in vivo model of contact hypersensitivity. J Dermatol Sci. 1999 Nov;21(3):170-5. PubMed PMID: 10527378. 14: Ogiso T, Iwaki M, Tanaka H, Kobayashi E, Tanino T, Sawada A, Uno S. Pharmacokinetic drug interactions between ampiroxicam and sulfaphenazole in rats. Biol Pharm Bull. 1999 Feb;22(2):191-6. PubMed PMID: 10077440. 15: Chishiki M, Kawada A, Fujioka A, Hiruma M, Ishibashi A, Banba H. Photosensitivity due to ampiroxicam. Dermatology. 1997;195(4):409-10. PubMed PMID: 9529571. 16: Toyohara A, Chen KR, Miyakawa S, Inada M, Ishiko A. Ampiroxicam-induced photosensitivity. Contact Dermatitis. 1996 Aug;35(2):101-2. PubMed PMID: 8917829. 17: Kurumaji Y. Ampiroxicam-induced photosensitivity. Contact Dermatitis. 1996 Apr;34(4):298-9. PubMed PMID: 8730175. 18: Olkkola KT, Brunetto AV, Mattila MJ. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin Pharmacokinet. 1994 Feb;26(2):107-20. Review. PubMed PMID: 8162655. 19: Carty TJ, Marfat A, Moore PF, Falkner FC, Twomey TM, Weissman A. Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam. Agents Actions. 1993 Jul;39(3-4):157-65. PubMed PMID: 8304243. 20: Falkner FC, Twomey TM, Borgers AP, Garg D, Weidler D, Gerber N, Browder IW. Disposition of ampiroxicam, a prodrug of piroxicam, in man. Xenobiotica. 1990 Jun;20(6):645-52. PubMed PMID: 2219958.

View History

Amperozide HCl